Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 118,914 shares at $1.95 ($232K) on 2015-03-23, disclosed to the SEC on 2015-03-24.
Scheduled sale ($232k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.94 | 59,784 | $116K | 50.0% |
| 2 | $1.95 | 1,600 | $3K | 1.3% |
| 3 | $1.96 | 28,197 | $55K | 23.8% |
| 4 | $1.96 | 7,903 | $15K | 6.7% |
| 5 | $1.97 | 5,184 | $10K | 4.4% |
| 6 | $1.97 | 11,700 |
| $23K |
| 9.9% |
| 7 | $1.98 | 2,216 | $4K | 1.9% |
| 8 | $1.98 | 2,330 | $5K | 2.0% |
| Total | $1.95 avg | 118,914 | $232K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |